Skip to main content

Table 1 Cisplatin-based conventional chemotherapy regimens and their efficacy against malignant pleural mesothelioma

From: A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report

Lead author/reference Chemotherapy regimen Admissions interval (median courses) Number of patients Response rate Median survival (months)
Vogelzang [14] Cisplatin (75mg/m2 on day one)/pemetrexed (500mg/m2 on day one) Every three weeks, 6.0 courses 226 41 percent 12.1
Nakano [15] Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15) Every four weeks, 2.6 courses 15 27 percent 6.5
Tsavaris [16] Cisplatin (100mg/m2 on day one)/vinblastine (6mg/m2 on days one and eight) Every four weeks, 4.0 courses 20 25 percent N/A
Ardizzoni [17] Cisplatin (60mg/m2 on day 1)/doxorubicin (60mg/m2 on day one) Every three to four weeks, 3.0 to 4.0 courses 26 25 percent 10
Nowak [18] Cisplatin (100mg/m2 on day one)/gemcitabine (1000mg/m2 on days one, eight, and 15) Every four weeks, 4.0 courses 53 33 percent 11.2
Present report Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15) One course with hyperthermia   Complete response >84
  1. N/A, not applicable.